Literature DB >> 26874706

New Diagnostic and Therapeutic Strategies for Pulmonary Hypertension Associated with Left Heart Disease.

Scott Feitell1, Miriam Jacob2.   

Abstract

OPINION STATEMENT: Pulmonary hypertension associated with left heart disease (PH-LHD) is a challenging entity to both diagnose and treat. A lack of consensus definitions, poorly understood pathophysiology, and the dynamic nature of hemodynamic assessments make this disease entity both underrecognized and misdiagnosed frequently. Diagnosing PH-LHD is crucial, because it not only alters management, but also has a direct effect on morbidity and mortality and ultimately leads to worse outcomes in this patient population. Though medical management remains challenging in these patients, an appropriate diagnosis, with careful assessment of hemodynamic parameters, can allow for appropriate advanced medical therapies and for improved quality of life.

Entities:  

Keywords:  Heart failure; Left heart disease; Pulmonary hypertension

Year:  2016        PMID: 26874706     DOI: 10.1007/s11936-016-0438-x

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  56 in total

1.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.

Authors:  William T Abraham; Philip B Adamson; Robert C Bourge; Mark F Aaron; Maria Rosa Costanzo; Lynne W Stevenson; Warren Strickland; Suresh Neelagaru; Nirav Raval; Steven Krueger; Stanislav Weiner; David Shavelle; Bradley Jeffries; Jay S Yadav
Journal:  Lancet       Date:  2011-02-19       Impact factor: 79.321

2.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management.

Authors:  D L Moraes; W S Colucci; M M Givertz
Journal:  Circulation       Date:  2000-10-03       Impact factor: 29.690

3.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.

Authors:  Milton Packer; John McMurray; Barry M Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L Demets
Journal:  J Card Fail       Date:  2005-02       Impact factor: 5.712

4.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

5.  Association of the metabolic syndrome with pulmonary venous hypertension.

Authors:  Ivan M Robbins; John H Newman; Roger F Johnson; Anna R Hemnes; Richard D Fremont; Robert N Piana; David X Zhao; Daniel W Byrne
Journal:  Chest       Date:  2009-02-02       Impact factor: 9.410

6.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

8.  Hemodynamic effects of inhaled nitric oxide in heart failure.

Authors:  M J Semigran; B A Cockrill; R Kacmarek; B T Thompson; W M Zapol; G W Dec; M A Fifer
Journal:  J Am Coll Cardiol       Date:  1994-10       Impact factor: 24.094

9.  Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure.

Authors:  Wayne L Miller; Diane E Grill; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2013-08-05       Impact factor: 12.035

10.  PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Authors:  Ryan J Tedford; Anna R Hemnes; Stuart D Russell; Ilan S Wittstein; Mobusher Mahmud; Ari L Zaiman; Stephen C Mathai; David R Thiemann; Paul M Hassoun; Reda E Girgis; Jonathan B Orens; Ashish S Shah; David Yuh; John V Conte; Hunter C Champion
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.